戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 and prednisone) alone or in conjunction with photopheresis.
2 disease patients treated with extracorporeal photopheresis, a form of systemic PUVA.
3 titox, mycophenolate mofetil, extracorporeal photopheresis, and several monoclonal antibodies have be
4 odality fashion with combined extracorporeal photopheresis, bexarotene, interferon-y, and low-dose TS
5 tosis in patients clearing on extracorporeal photopheresis but persisted in nonresponsive patients.
6 ted with clinical response to extracorporeal photopheresis (ECP) and mortality after ECP in lung allo
7 ty is preserved in mice after extracorporeal photopheresis (ECP) but reduced with glucocorticosteroid
8    The safety and efficacy of extracorporeal photopheresis (ECP) for 12 to 24 weeks together with sta
9                               Extracorporeal photopheresis (ECP) has demonstrated therapeutic benefit
10                               Extracorporeal photopheresis (ECP) has emerged as a prophylactic and th
11                               Extracorporeal photopheresis (ECP) is a widely used clinical cell-based
12                               Extracorporeal Photopheresis (ECP) is an autologous cell-based immunoth
13                               Extracorporeal photopheresis (ECP) is an immunomodulatory therapy curre
14                               Extracorporeal photopheresis (ECP) is an important therapeutic option i
15                               Extracorporeal photopheresis (ECP) is considered a valid second-line tr
16 gulatory T (Treg) cells after extracorporeal photopheresis (ECP) is thought to contribute to how ECP
17                               Extracorporeal photopheresis (ECP), a technique that exposes isolated w
18                               Extracorporeal photopheresis (ECP), an immunomodulating procedure that
19  disease (cGVHD) treated with extracorporeal photopheresis (ECP).
20   Apoptosis can be induced by extracorporeal photopheresis (ECP).
21 py group, as compared with 0.91+/-1.0 in the photopheresis group (P=0.04).
22           Significantly more patients in the photopheresis group had one rejection episode or none (2
23 27), and significantly fewer patients in the photopheresis group had two or more rejection episodes (
24                                          The photopheresis group received a total of 24 photopheresis
25 etected significantly less frequently in the photopheresis group than in the standard-therapy group (
26 bexarotene, interferon alpha, extracorporeal photopheresis, histone deacetylase inhibitors, and antib
27 y study to assess the safety and efficacy of photopheresis in the prevention of acute rejection of ca
28                                              Photopheresis is an immunoregulatory technique in which
29                               Extracorporeal photopheresis is confirmed as an effective second-line t
30 nti-LFA-3-IgG fusion protein, extracorporeal photopheresis, mesenchymal stem cells and regulatory T c
31  systemic immunosuppressants, extracorporeal photopheresis, or phototherapy.
32 ts for chronic GVHD including extracorporeal photopheresis, rituximab, sirolimus, mycofenolate mofeti
33 loaded dendritic cells as well as the use of photopheresis to generate an anti-idiotype cytotoxic T-c
34         In this pilot study, the addition of photopheresis to triple-drug immunosuppressive therapy s
35 e photopheresis group received a total of 24 photopheresis treatments, each pair of treatments given